Show Footer Banners
Age Concerns Everyone Conference 2018
When: 16-17 April
Where: James Cook Hotel Grand Chancellor, Wellington
Who should attend? As the conference name suggests - EVERYONE!
We are all ageing so we should all have a say on how we shape the future so we all get to live out our later lives with choice, dignity and respect. Let your colleagues, family or friends and community know so that they can join in the conversation too!
It is big, exciting and packed with opportunity!
- Minister for Seniors, Hon Tracey Martin is opening the conference
- 52 speakers
- 18 sponsors
- 200 delegates
- Speaker topics include: health, housing, older workers, social connection initiatives, Māori perspectives on ageing, The World of LGBTI, scamming and cyber security, crime and prison communities and more.
Please register now for the Age Concerns Everyone conference.
Lymphoedema Support Network Meeting
The next Lymphoedema Support Network meeting will be addressed by speaker Karin Horen, who has twice survived breast cancer. She will speak about Paddle for Hope, her experiences on the water since 2009 and becoming an international Paddle Boarder. All welcome.
For more information please contact Joy Donohoe on email@example.com
When: Monday 26th March at 7.30 p.m.
Where: Domain Lodge (Auckland Cancer Society), 1 Boyle Cres. (off Park Rd), Grafton, Auckland. Parking available in building.
You are invited to register to attend the upcoming webinar, Palbociclib (Ibrance) for metastatic ER+ breast cancer - NZ update, presented by Breast Cancer Foundation NZ (BCFNZ) with Dr Richard Finn (USA). Palbociclib (brand name Ibrance) is a new medicine for advanced ER+ breast cancer that has achieved significant results in high-profile clinical trials overseas. It’s not funded in New Zealand, but some Kiwis have been buying it off-shore, and there will soon be compassionate access for NZ patients that will make it potentially more affordable.
When: Monday March 19th, 2018
Duration: 60 minutes
Where: Online - wherever you like!
Presented by: Breast Cancer Foundation NZ
To regsiter, please click here.
Meet your panel
Dr Richard Finn, is associate professor of Medicine at the UCLA David Geffen School of Medicine. He led the PALOMA series of clinical trials for palbociclib and is considered one of the world’s foremost experts on this new drug.
BCFNZ also hope to have a NZ oncologist on the panel, but this is yet to be confirmed.
What will you get out of this session?
This session will give you a run-down on what palbociclib is, how it works and who for; where it sits among treatments for advanced ER+ breast cancer; opportunities in NZ for clinical trials and compassionate access to palbociclib; paying privately, and discussing palbociclib with your oncologist.
To register, please click here.
Breast Cancer Support (BCS) Inc. Annual General Meeting
When: Monday, 12 March 2018, 7 pm
Where: Domain Lodge (Auckland Cancer Society), 1 Boyle Cres, Grafton, Auckland
Guest speaker: Physiotherapist Megan Schmidt of Active+ Albany
Next Steps, PINC and PaddleOn! - Exercise programmes aiding recovery from breast cancer
Megan (pictured right) has 20 years’ experience as a private musculo-skeletal physiotherapist and has trained as a lymphoedema therapist in Sydney under the Australasian Lymphology Association guidelines. For the past 10 years Megan has specialised in cancer rehabilitation, and she has extensive knowledge and experience in the treatment of all cancer related issues and lymphoedema. She is on the PINC & STEEL International medical advisory committee and runs the PINC, PaddleOn and Next Steps rehabilitation programmes from her physiotherapy practice in Albany.
The following documents will be available at the meeting or prior to the meeting upon request: the Annual Report and Statement of Accounts, a list of nominees for the Committee, notice of any motions to be considered, and the Committee's recommendations about those motions.
Light refreshments will be served.
All are welcome to attend, and the BCS team look forward to seeing you. Parking is available at the venue: please check in with Reception on arrival for entry to the secure parking area.
For more information, please call 0800 273 222 or email firstname.lastname@example.org
This is a randomised controlled trial which will investigate whether Radio-guided Occult Lesion Localisation using Iodine-125 Seeds (ROLLIS) for the removal of impalpable (not able to be felt) breast cancer can reduce the rate of inadequate margins and/or subsequent oncological surgery compared with standard hook-wire localisation.
Approximately one-third of breast cancers are non-palpable (i.e. not able to be felt). The success of mammographic screening programmes has seen an increase in the number of women diagnosed with non-palpable breast cancers eligible for breast conserving surgery. To minimize the risk of local recurrence, complete removal of the breast cancer with tumour clear of the margins of excision is needed. Where the remainder of the breast is conserved, this is called breast conserving surgery (BCS). The reported incidence of inadequate margins (e.g. tumour right up to the margin) with BCS internationally is between 20-70%, in many cases leading to re-excision or mastectomy.
Hook-wire localisation (HWL) is the most commonly used method of marking or localising a lesion and involves a radiologist inserting a thin hook-wire into the lesion using ultrasound or xray guidance. This procedure is done after an injection of local anaesthetic. The hook-wire is used by the surgeon at the time of operation, to locate the lesion so that it can be removed together with the wire. The use of a hook-wire to guide surgery is complex and the wire needs to be inserted on the day of surgery. Sometimes the wire can move from its initial position. As a result, or for other reasons, sometimes not all of the tumour is removed during the operation. This may mean another operation; “re-excision”, or mastectomy.
The re-excision rate using hook wire guided BCS in two large Western Australian hospitals in 2009 was 30%. The re-excision rate at Waikato Hospital from 2000-2014 is on average 26%; and from breast cancers detected by screening mammography, is 23%. A proportion of these cases are due to non-modifiable factors such as preoperative underestimation of the extent of disease. However, re-excision rate can also be attributed to the technique used for lesion localisation and removal.
Radio-guided occult lesion localization using iodine-125 seeds (or “ROLLIS”) is a new technique in Australasia being trialled. This involves the insertion of a low-activity radioactive iodine-125 (I-125) seed into the breast lesion. During the surgery, a hand-held detecting “probe” is used by the surgeon to detect the radioactive signal produced by the seed. The seed and the abnormal area will then be removed. The seed insertion can be done up to eight days before surgery, improving surgical scheduling and patient convenience. ROLLIS has been reported to be associated with reduced rates of involved (with cancer) surgical margins, shorter operating times and improved ease of use in comparison to HWL.
The ROLLIS method for marking breast lesions has been used overseas for a number of years. The Waikato Breast Care Centre is the only New Zealand participating centre for this Western Australian coordinated multicentre randomised controlled trial (RCT) which will introduce the ROLLIS technique to Australia and New Zealand and ensure that it is safe and effective. Please speak to your medical team if you are interested in this trial.